Valuation
- Market cap
- 215,933,000
- Revenue TTM
- $52,740,000
- Net income TTM
- $-6,600,000
- PE ratio
- 12.00
- Forward PE
- 11.50
- Profit margin
- -12.51%
- Debt to equity
- 0.00
Trading
- Volume
- 947,400
- Avg volume
- 761,746
- Day's range
- $2.64 – $2.72
- Shares out
- 80,572,000
- Stochastic %K
- 44%
- Beta
- -0.09
- Analysts
- Strong Sell
- Price target
- $11.00
Company profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a...
Show more
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 201 696 9345
- Website
- https://www.protalix.com
- Address
- 2 University Plaza, Suite 100, Hackensack, United States
Latest news
No headlines yet.
Stocktwits
calemay
Oct 3, 1:44 AM
$PLX
This thing has been a gem for about 10 years….just needs about 10 more I think
2 replies
CliffordCapital
Oct 2, 7:56 PM
$PLX big accumulation today. Pinning it between 2.70$ and 2.71$… nicely done.
0 replies
CliffordCapital
Oct 2, 1:55 PM
$PLX happy new NQ100 heights! If I had put the money on the NQ instead of here in April 25 I would be up 60% already.. 🤣 this investment sucks! 😂
2 replies
brunoq14
Oct 2, 10:23 AM
$PLX Now that we know that Chiesi has been negotiating with the FDA about extending the monthly dosing option for Elfabrio to the United States, because of the CFO's remarks at the Morgan Stanley conference, can we consider it a positive that we have not been informed of any additional conditions set by the FDA for such a development, which is after all only an option at the discretion of patient and physician?
0 replies
PickStocker
Oct 2, 6:33 AM
$PLX Rises above 2.80 - "Damn, why didn’t I buy more of this gem?"
Drops below 2.70 - "Oh no… not again."
It’s hard not to get emotional with this one. 😅
1 replies
jcon777
Oct 2, 4:02 AM
$PLX I also asked Gemini which top 10 countries are likely to adopt the once a month dosing the fastest:
Based on standard pharmaceutical market access trends in Europe, the top 10 countries expected to be the fastest to transition stable Fabry disease patients to the monthly regimen include:
1. Germany Why: Germany grants immediate market access upon EU approval, allowing statutory health funds to cover new indications or dosing variations while official reimbursement negotiations take place over the first year.
2. Austria Why: Austria closely mirrors German pharmaceutical uptake and typically adopts centralized European label changes with minimal local administrative lag.
3. Denmark Why: Denmark has a highly digitized, streamlined hospital-driven procurement framework for rare diseases, allowing fast-track implementation via specialized metabolic centers.
1 replies
jcon777
Oct 2, 3:51 AM
$PLX With an AI search, I asked Gemini about how long till some of the European countries actually have the once a month dosing for Elfabrio in routine clinical practice. As a reminder, once a month dosing was approved in March this year. Below is the answer:
-----------------------------------------------------
For specialized rare disease treatments like enzyme replacement therapies (ERTs), the transition into routine clinical practice typically takes about 3 to 12 months following European Commission approval.
0 replies
CliffordCapital
Oct 1, 7:33 PM
$PLX good volume today! Wrong direction thought lol
1 replies
